EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands

Katarina Sjögreen Gleisner*, Nicolas Chouin, Pablo Minguez Gabina, Francesco Cicone, Silvano Gnesin, Caroline Stokke, Mark Konijnenberg, Marta Cremonesi, Frederik A. Verburg, Peter Bernhardt, Uta Eberlein, Jonathan Gear

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

86 Citations (Scopus)
6 Downloads (Pure)

Abstract

The purpose of the EANM Dosimetry Committee is to provide recommendations and guidance to scientists and clinicians on patient-specific dosimetry. Radiopharmaceuticals labelled with lutetium-177 (177Lu) are increasingly used for therapeutic applications, in particular for the treatment of metastatic neuroendocrine tumours using ligands for somatostatin receptors and prostate adenocarcinoma with small-molecule PSMA-targeting ligands. This paper provides an overview of reported dosimetry data for these therapies and summarises current knowledge about radiation-induced side effects on normal tissues and dose-effect relationships for tumours. Dosimetry methods and data are summarised for kidneys, bone marrow, salivary glands, lacrimal glands, pituitary glands, tumours, and the skin in case of radiopharmaceutical extravasation. Where applicable, taking into account the present status of the field and recent evidence in the literature, guidance is provided. The purpose of these recommendations is to encourage the practice of patient-specific dosimetry in therapy with 177Lu-labelled compounds. The proposed methods should be within the scope of centres offering therapy with 177Lu-labelled ligands for somatostatin receptors or small-molecule PSMA.

Original languageEnglish
Pages (from-to)1778-1809
Number of pages32
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume49
Issue number6
DOIs
Publication statusPublished - May 2022

Bibliographical note

Funding Information:
The guidelines were brought to the attention of the relevant EANM Committees and the National Societies of Nuclear Medicine. The comments and suggestions from the EANM Radiation Protection Committee and the French and British National Societies are highly appreciated and have been considered for this guideline.

Funding Information:
Open access funding provided by Lund University. Economic support was granted by the Swedish Cancer Society (180747, 211754Pj01H) and Mrs. Berta Kamprad’s Foundation (BKS-2020-13) (Sjögreen Gleisner).

Publisher Copyright:
© 2022, The Author(s).

Fingerprint

Dive into the research topics of 'EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands'. Together they form a unique fingerprint.

Cite this